Cannabis Science Inc (OTCMKTS:CBIS) is moving up quickly since a brief dip below $0.03 on massive volume as pot stocks heat up across the board. As evidenced by recent trading CBIS is a great place to be when pot stocks heat up. The Company is one of the original Marijuana plays to hit the BB’s back in 2009. Over the past several years as Marijuana stocks have heated up CBIS has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs.
CBIS is running fast as pot stocks have heated up going into the election. The red hot Marijuana industry has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states legalizing the drug including California and Massachusetts last week.
Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:
The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”
The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”
To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.
The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.
CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.
On November 10 CBIS announced it is prepared to move in on new opportunities in California and Nevada markets following the election cycle. The Company is now targeting over 1,000 acres in California and Nevada for property and drug development programs. The post-election plan includes new products, new dispensaries, and new strategic agreements.
“After closing the last land deal we announced for over 300 acres, we are now on to something much larger on a combined scale. This land package goes right in line with our other large deals in California and Nevada. These land deals put us in a very favorable position for high growth moving forward. Coupled with completing our in-house laboratory, new drug programs, and our new website, we have some very exciting developments coming in the near future and we feel ready to meet the demands of more patients than ever before, and the timing couldn’t be better. With the tremendous support for Proposition 64 and other pro-cannabis initiatives across the nation Cannabis Science is positioned to become a market leader,” said Director, President, CEO & Co-Founder, Raymond C. Dabney.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $94 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is currently testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media. CBIS is a great place to be when pot stocks heat up as they are right now leading up to November 8. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.